Core Viewpoint - The company reported a significant decline in revenue and an increase in net losses for the third quarter of 2025, indicating ongoing financial challenges and the need for strategic transformation [1] Financial Performance - For the third quarter, the company's revenue was 274 million, a year-on-year decrease of 38.4% [1] - The net loss for the third quarter improved slightly to 31.12 million from a loss of 51.25 million in the same period last year [1] - Year-to-date revenue for 2025 was 857 million, down 39.6% compared to the previous year [1] - The net loss for the year-to-date period increased to 87.24 million from a loss of 56.03 million in the previous year [1] - Total assets as of the end of the third quarter were 2.09 billion, a decrease of 26.1% from the end of the previous year [1] - The company's net assets increased by 16.8% to 1.091 billion compared to the end of the previous year [1] Strategic Focus - The company is focusing on core business areas and optimizing its operational structure while undergoing a strategic transformation towards medical intelligence [1] - The decline in revenue and gross profit was attributed to the transfer of equity in some subsidiaries during the reporting period [1] - To enhance profitability, the company has strengthened cost control, resulting in a combined reduction of 18.54% in sales, management, and financial expenses [1] - The report indicated that the company recognized credit impairment losses, which impacted operating profits [1] Business Operations - The company's main business includes medical supply chain services and the research and sales of related products, aiming to provide efficient medical services and solutions to clients [1] - The company plans to continue optimizing its business structure and upgrading its operations to respond to market changes and industry challenges [1]

Group 1 - The issuer and other responsible entities have made commitments related to the issuance and listing of the company [1] - There is a specific commitment regarding information disclosure for shareholders of Shanghai Jianda Zhi Xin Medical Supply Chain Management Group Co., Ltd [1]

Group 1 - Fujian Sanji Medical Supply Chain Co., Ltd. was recently established with a registered capital of 10 million RMB, and the legal representative is Luo Jihan [1] - The shareholders of the company are Xiamen Sanji Investment Co., Ltd. holding 51% and Xiamen Xiangminghua Medical Equipment Co., Ltd. holding 49% [2] - The company's business scope includes supply chain management services, sales and leasing of various medical devices, retail and wholesale of medical masks, and technical services among others [2] Group 2 - The company is classified under the national standard industry of transportation, storage, and postal services, specifically in the handling and storage sector [3] - The registered address of the company is located at 16 Hutu Road, Haicang District, Xiamen City, on the fifth floor, Area B [3] - The company is a limited liability company with a natural person as an investor or controller, and its business term is set until July 23, 2025, with no fixed expiration [3]